Physician profile
Peggy E Jesse
NPI 1790811057
$1,087.97
in general payments reported to CMS, 2019-2025
14 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.25 · 2022: $284 · 2023: $255 · 2024: $91.81 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $333.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $209.65 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $122.15 | 2021-2025 | Eliquis |
| Pfizer INC. | $117.68 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $77.92 | 2025 | Rexulti |
| Amgen INC. | $47.42 | 2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $35.93 | 2021-2023 | Farxiga |
| Glaxosmithkline, LLC. | $23.95 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $23.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.24 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.93 | 2025 | Caplyta |
| Lilly USA, LLC | $20.63 | 2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $17.95 | 2022 | |
| Organon LLC | $12.81 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggy Jesse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.